Department of Health Science, University Magna Græcia of Catanzaro, Catanzaro, Italy.
Biomed Res Int. 2013;2013:104315. doi: 10.1155/2013/104315. Epub 2013 Jun 18.
Current advances in the knowledge of asthma pathobiology suggest that anticytokine therapies can be potentially useful for the treatment of this complex and heterogeneous airway disease. Recent evidence is accumulating in support of the efficacy of anti-IL-4, anti-IL-5, and anti-IL-13 drugs. Therefore, these new developments are now changing the global scenario of antiasthma therapies, especially with regard to more severe disease. Current findings referring to variability of individual therapeutic responses highlight that the different asthma subtypes need to be well characterized, in order to implement phenotype-targeted treatments which in the near future will hopefully be mainly based on cytokine-directed biologics.
目前，哮喘病理生物学知识的进展表明，细胞因子疗法可能对治疗这种复杂和异质性的气道疾病具有潜在的作用。越来越多的证据支持抗 IL-4、抗 IL-5 和抗 IL-13 药物的疗效。因此，这些新的发展正在改变全球的哮喘治疗方案，尤其是在更严重的疾病方面。目前关于个体治疗反应变异性的研究结果表明，不同的哮喘亚型需要进行充分的特征描述，以便实施针对表型的治疗，在不久的将来，希望主要基于细胞因子导向的生物制剂。
